Gene Editing's 2026 Reality Check: Billion-Dollar Bets and the AI HorizonGlobal Report·1 day ago, 04:17 AMVRTX+0.11%CRSP+0.61%
The Silent Rotation: Inside the Moves of 10 Niche Tech and Defense PlayersGlobal Report·2 days ago, 04:12 AMTWLO+0.92%KTOS+3.24%
The Great Biotech Reckoning: When AI and Gene Editing Meet Wall Street's Patience in 2026Global Report·Jul 19 at 04:13 AMAMGN+1.48%CRSP+0.61%
M&A, AI Drug Discovery, and Late-Stage Clinical Readouts Define US Biotech Q2 TrajectoryGlobal Report·Jul 18 at 04:13 AMAMGN+1.48%CRSP+0.61%
10 Health Care Stocks With Whale Alerts In Today’s Sessionbenzinga_article·Jul 1 at 12:35 PMCRSP+0.61%PURR-4.96%
HCA Healthcare says NEJM study shows CRISPR therapy exa-cel hits 12-month endpoints in children 5-11 with sickle cell, beta thalassemiaPUBT·Jun 29 at 07:30 AMHCA+1.25%CRSP+0.61%
Gil Blum Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target on Pipeline Upside and 2026 Data CatalystsTip Ranks·Jun 24 at 08:15 AMCRSP+0.61%
Why CRISPR Therapeutics stock has been on a roller-coaster ride this yearMSN·Jun 18 at 09:13 AMCRSP+0.61%
Divergent Signals in an Unclassified Cohort: Cross-Border Catalysts and Downside Risks Across 42 EquitiesGlobal Report·Jun 18 at 08:18 AMHNST-3.13%FRO+2.34%
Biotech Sector Sees Crucial Clinical Readouts as Three Firms Advance Pipeline CommercializationGlobal Report·Jun 18 at 04:15 AMCRSP+0.61%RVMD+3.13%
CRISPR Therapeutics (CRSP) Stock Valuation Check After Recent Pullback And Conflicting DCF And P/B SignalsSimplywall·Jun 13 at 04:33 AMCRSP+0.61%
CRISPR Therapeutics AG Stock 12‑Month Price Target Cut to $81.1, Implies 64% UpsideTradingView·Jun 11 at 02:20 AMCRSP+0.61%
Kivo and CRISPR Therapeutics to Present 52-Day QMS Modernization at DIA 2026 in Philadelphiabiopharmadive·Jun 9 at 08:03 AMCRSP+0.61%
CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potentialnasdaq·Jun 3 at 12:00 PMCRSP+0.61%
